Skip to main content
Equibles

Bryan Giraudo

CEO

Gossamer Bio, Inc. (GOSS)

CFO

Gossamer Bio, Inc. (GOSS)

COO

Gossamer Bio, Inc. (GOSS)

Equibles does not estimate personal net worth.

Get an email with a short summary when Gossamer Bio, Inc. publishes a filing, an earnings call transcript or a press release.

Get GOSS alerts

About Bryan Giraudo

Bryan Giraudo is recorded as COO at Gossamer Bio, Inc. (GOSS) since September 16, 2021 and CEO and CFO at Gossamer Bio, Inc. (GOSS). The newest filing on record that lists Bryan Giraudo as CFO at Gossamer Bio, Inc. (GOSS) is dated April 24, 2026. The proxy statement of Gossamer Bio, Inc. reports total compensation of $1,253,431 for Bryan Giraudo in fiscal 2025, including a base salary of $519,830. Disclosed compensation is on record for 8 fiscal years. Bryan Giraudo has spoken on 9 earnings calls across 1 company, most recently for Gossamer Bio, Inc. on July 27, 2026. Gossamer Bio, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Gossamer Bio, Inc. includes Faheem Hasnain (CEO and Chairman), Christian Waage (General Counsel), Gregory A. Ciongoli (Board Member) and 7 others.

Bryan Giraudo on recent calls

“Earlier today, we issued a press release announcing several important updates for Gossamer.”
CFO, Gossamer Bio, Inc. Q2 FY2026 Earnings Call ·
“Before we begin, I'd like to remind listeners that today's discussion includes forward-looking statements, including statements regarding our regulatory plans, potential NDA submission, and approval timing, commercialization, expectations, cash runway, capital structure, and the potential therapeutic benefit in future…”
COO, Gossamer Bio, Inc. Q1 FY2026 Earnings Call ·
“I am joined on today's call by Faheem Hasnain, Gossamer's Founder, Chairman, and Chief Executive Officer; Dr. Richard Aranda, Chief Medical Officer; Caryn Peterson, Executive Vice President, Regulatory Affairs; and Bob Smith, Chief Commercial Officer.”
COO, Gossamer Bio, Inc. Q1 FY2025 Earnings Call ·
“I am joined on today's call by Gossamer's Co-Founder, Chairman and Chief Executive Officer, Faheem Hasnain; Gossamer's Chief Medical Officer, Dr. Richard Aranda; and Gossamer's Chief Scientific Officer, Dr. Laura Carter.”
CEO, Gossamer Bio, Inc. Q4 FY2021 Earnings Call ·
“I am joined on today's call by Gossamer Bio's Chairmen, Co-Founder, Chief Executive Officer, Faheem Hasnain; Laura Carter, Gossamer Bio's Chief Scientific Officer; and Richard Aranda, Gossamer Bio's Chief Medical Officer.”
CFO, Gossamer Bio, Inc. Q3 FY2021 Earnings Call ·

Affiliation history

Company network

Leadership on record at Gossamer Bio, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Gossamer Bio, Inc. (GOSS) $519,830 $1,253,431
2024 Gossamer Bio, Inc. (GOSS) $502,645 $1,171,904
2023 Gossamer Bio, Inc. (GOSS) $485,624 $1,287,882
2022 Gossamer Bio, Inc. (GOSS) $473,418 $3,268,699
2021 Gossamer Bio, Inc. (GOSS) $438,492 $2,825,437
2020 Gossamer Bio, Inc. (GOSS) $416,667 $2,014,958
2019 Gossamer Bio, Inc. (GOSS) $400,000 $2,647,282
2018 Gossamer Bio, Inc. (GOSS) $260,605 $2,192,515

Recent activity